EC
CRNX icon

EntryPoint Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

EntryPoint Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,388
Closed -$315K – 652
2025
Q1 		$315K Buy
+9,388
New +$351K 0.14% 295
2024
Q3 		– Sell
-2,845
Closed -$127K – 727
2024
Q2 		$127K Buy
+2,845
New +$131K 0.19% 201

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EntryPoint Capital's CRNX Position: Q2 2025 in Review

EntryPoint Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 9,388 shares — an estimated $315K sold.

EntryPoint Capital first reported a position in CRNX in Q2 2024 and held it in 2 quarters. The position peaked at $315K in Q1 2025. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • EntryPoint Capital reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • EntryPoint Capital sold 9,388 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $315K.
  • EntryPoint Capital first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • EntryPoint Capital's Crinetics Pharmaceuticals position peaked at $315K in Q1 2025.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.